MC1R
Ongoing clinical trials and approved products targeting MC1R, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.
2ongoing therapy trials
0ongoing imaging trials
0approved products
Target note
- Full name
- Melanocortin 1 receptor
- Nature
- G protein-coupled receptor for the melanotropic hormone α-MSH.
- Normal expression
- Melanocytes.
- Disease expression
- Cutaneous melanoma and metastatic uveal melanoma.
- Value
- An option in metastatic uveal melanoma, where treatments are few.
- Approaches
- α-MSH analogue peptides (VMT01) labeled with ²¹²Pb, MTI-201 labeled with ²²⁵Ac.
- Indications explored
- MC1R-positive metastatic melanoma, as monotherapy or with immunotherapy.
- Points of caution
- Renal retention of peptides; early data.
| Trial | Phase | Status | Sponsor | Countries |
|---|
| [212Pb]VMT01NCT05655312 · Melanoma | Phase 2 | Recruiting | Perspective Therapeutics | 1 |
| [225Ac]MTI-201NCT05496686 · Melanoma | Phase 1 | Active, not recruiting | Modulation Therapeutics, Inc. | 1 |
Cite this page
MC1R. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/mc1r/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.